Form 4: Immuneering Chief Business Officer Buys 1,900 Shares in Open Market Transaction

Immuneering Corp.'s Chief Business Officer, Harold Eugene Brakewood, increased his stake in the company by purchasing 1,900 shares of Class A Common Stock.

Summary

• Harold Eugene Brakewood, Chief Business Officer of Immuneering Corp. (IMRX), acquired 1,900 shares of the company's Class A Common Stock.
• The transaction occurred on June 20, 2025, at a price of $2.5285 per share.
• Following this purchase, Mr. Brakewood directly beneficially owns a total of 5,800 shares of Class A Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 8

Explanation: The purchase of shares by a high-ranking officer (Chief Business Officer) indicates strong insider confidence, which is generally viewed positively by the market.

Positives

• An insider, the Chief Business Officer, purchased additional shares, indicating confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned investment strategy.

Risks

• This Form 4 filing does not contain information regarding company-specific risks or future challenges; it solely reports an insider trading transaction.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future outlook; it is a report of a past insider transaction.

Industry Context

This filing reports an individual insider stock purchase and does not provide broader industry trends or competitive analysis. However, insider buying can be seen as a positive signal within the biotechnology or pharmaceutical industry, indicating management's belief in the company's drug pipeline or strategic direction.

Comparison to Industry Standards

• Not applicable to this document type as it reports an individual insider transaction, not company performance metrics or project results that can be directly compared to industry benchmarks or specific comparable companies.

Related Party Transactions

• The reported transaction is a related party transaction, as it involves the purchase of company stock by a corporate officer.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign, potentially increasing confidence in the company's stock.
• Employees may interpret this as a sign of stability and positive internal outlook from leadership.

Key Dates

Recommendation

Keywords

Immuneering Corp, IMRX, Insider Trading, Form 4, Stock Purchase, Chief Business Officer, Harold Eugene Brakewood, Equity Acquisition, Rule 10b5-1